The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBritish American Tobacco Regulatory News (BATS)

Share Price Information for British American Tobacco (BATS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,387.00
Bid: 2,387.00
Ask: 2,388.00
Change: 32.00 (1.36%)
Spread: 1.00 (0.042%)
Open: 2,366.00
High: 2,402.00
Low: 2,363.00
Prev. Close: 2,355.00
BATS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BAT Response to FDA Flavour Guidance

3 Jan 2020 07:00

RNS Number : 6200Y
British American Tobacco PLC
03 January 2020
 

British American Tobacco p.l.c.

 

3 January 2020

 

BRITISH AMERICAN TOBACCO WELCOMES FDA GUIDANCE AS A FURTHER STEP TOWARD A SUSTAINABLE REGULATORY ENVIRONMENT FOR THE US VAPOUR MARKET

 

·; British American Tobacco (BAT) welcomes the U.S. FDA's acknowledgment that a properly regulated vapour category continues to provide a credible alternative to smoking

 

·; Appropriate enforcement will ensure the sustainability of adult consumer choice across all product categories

 

·; BAT's U.S. subsidiary, Reynolds American Inc. (RAI), stands ready to comply with the new flavour guidelines

 

·; RAI has already submitted its first brand PMTA application and is well positioned to make further applications for the rest of its vapour portfolio ahead of the May 2020 deadline

 

·; RAI is confident that, as required by the PMTA process, all VUSE products will be shown to be appropriate for the protection of public health

 

British American Tobacco (BAT) welcomes the U.S. FDA's acknowledgement that a properly regulated vapour category continues to provide a credible alternative to smoking, whilst also highlighting the important issue of preventing the access and appeal of vapour products to youth. Following a significant period of disruption and uncertainty, this regulatory clarity is a welcome step towards returning the US vapour market to stability.

 

British American Tobacco Chief Executive Officer, Mr Jack Bowles noted:

"Yesterday's announcement takes us a step closer to a predictable regulatory environment in a key marketplace, but focus must now shift to enforcement to ensure vapour market regulations are effective.

 

"We have long said it is not the marketing of these products per se that is the concern, it is the irresponsible marketing of them that should be robustly addressed. For us, smart regulatory frameworks partnered with responsible marketing and appropriate enforcement will ensure the sustainability of adult consumer choice across all categories."

 

The guidance the FDA has provided, together with the previously announced requirement to submit PMTAs by May 2020 for all products, is a positive step and will help ensure consumers have access to appropriately regulated, quality-assured products that do not appeal to or are accessible to youth.

 

Importantly, the guidance is clear that flavours can return to the market place once they have been cleared through the PMTA process.

 

Mr Bowles continued:

 

"Millions of adult tobacco consumers are looking for an alternative to cigarettes and it's important to remember that properly regulated flavours can play an important role in the choice of adult tobacco consumers to transition to vapour products as an alternative to cigarettes."

 

"Our US subsidiary, RAI Group, has already submitted one brand PMTA for VUSE Solo and is well positioned to submit applications for the remaining VUSE portfolio ahead of the deadline of May 2020. We are confident that, as required by the PMTA process, all VUSE products will be shown to be appropriate for the protection of public health."

 

BAT has long argued for sustainable regulatory frameworks for its new category products. BAT believes in providing adult consumers with vapour systems that are hard to adulterate; providing new category products which are supported by world class science and product stewardship; offering a range of flavours which ensure adult consumer satisfaction whilst not appealing to youth; and marketing freedoms to drive category adoption among adult consumers.

 

Mr Bowles concluded:

"We will continue to work with the U.S. FDA throughout the implementation of this new regulatory framework to make sure consumers have access to quality-assured products whilst doing our utmost to ensure that vaping remains positioned as a credible option for smokers looking for an alternative to tobacco."

 

 

Enquiries

Press Office+44 (0) 20 7845 2888 (24 hours) | @BATPress 

Investor RelationsMike Nightingale / Rachael Brierley / John Harney+44 (0) 20 7845 1180 / 1519 / 1263

 

Forward looking statements

References to 'British American Tobacco', 'BAT', 'we', 'us' and 'our' when denoting opinion refer to British American Tobacco p.l.c. (the Company, and together with its subsidiaries, the "Group"), and when denoting tobacco business activity refer to Group operating companies, collectively or individually as the case may be. This announcement contains certain forward-looking statements, including those made within the meaning of Section 21E of the United States Securities Exchange Act of 1934, regarding our intentions, beliefs or current expectations reflecting knowledge and information available at the time of preparation and concerning, amongst other things, prospects, growth, strategies, compliance with regulatory guidelines, our ability to submit further regulatory applications, the success of our regulatory applications and the economic and business circumstances occurring from time to time in the countries and markets in which the Group operates. BAT undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on such forward-looking statements.

 

These statements are often, but not always, made through the use of words or phrases such as "believe," "anticipate," "could," "may," "would," "should," "intend," "plan," "potential," "predict," "will," "estimate," "strategy" and similar expressions. It is believed that the expectations reflected in this announcement are reasonable but they may be affected by a wide range of variables that could cause actual results to differ materially from those currently anticipated, including uncertainties related to the impact of adverse domestic or international legislation and regulation and adverse decisions by domestic or international regulatory bodies.

 

Additional information concerning these and other factors can be found in the Company's filings with the U.S. Securities and Exchange Commission ("SEC"), including the Annual Report on Form 20-F filed on 15 March 2019 and Current Reports on Form 6-K, which may be obtained free of charge at the SEC's website, http://www.sec.gov, and the Company's Annual Reports, which may be obtained free of charge from the British American Tobacco website www.bat.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCLLLLBBFLXBBX
Date   Source Headline
28th Mar 20247:00 amRNSTransaction in Own Shares
27th Mar 20247:00 amRNSTransaction in Own Shares
26th Mar 20247:00 amRNSTransaction in Own Shares
25th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 202410:40 amRNSDirector/PDMR Shareholding
22nd Mar 202410:35 amRNSDirector/PDMR Shareholding
22nd Mar 202410:30 amRNSDirector/PDMR Shareholding
22nd Mar 20247:00 amRNSTransaction in Own Shares
21st Mar 20243:26 pmRNSDirector/PDMR Shareholding
21st Mar 20243:20 pmRNSDirector/PDMR Shareholding
21st Mar 20247:00 amRNSTransaction in Own Shares
20th Mar 20247:00 amRNSTransaction in Own Shares
19th Mar 20247:00 amRNSTransaction in Own Shares
18th Mar 20247:00 amRNSShare Buy-Back Programme
14th Mar 20248:00 amRNSNotice of AGM
13th Mar 20247:00 amRNSCompletion of Block Trade of ITC Shares
12th Mar 20243:40 pmRNSDirector/PDMR Shareholding
12th Mar 202411:25 amRNSLaunch of Proposed Block Trade of ITC Shares
11th Mar 20244:43 pmRNSResponse to Recent Speculation
11th Mar 20247:00 amRNSBranch Register: Dividend Finalisation Information
7th Mar 20242:20 pmRNSDirector/PDMR Shareholding
5th Mar 20244:30 pmRNSPublication of a Prospectus
4th Mar 20242:15 pmRNSDirector/PDMR Shareholding
1st Mar 202410:45 amRNSDirector/PDMR Shareholding
1st Mar 202410:40 amRNSTotal Voting Rights
21st Feb 202410:45 amRNSDirector/PDMR Shareholding
16th Feb 202411:30 amRNSPricing Notes Offering
15th Feb 20242:55 pmRNSDirector/PDMR Shareholding
13th Feb 20241:30 pmRNSPublication of Suppl.Prospcts
13th Feb 20249:55 amRNSDirector/PDMR Shareholding
9th Feb 20244:17 pmRNSAnnual Financial Report
8th Feb 202412:15 pmRNSDirector/PDMR Shareholding
8th Feb 20247:00 amRNSFinal Results
6th Feb 202410:10 amRNSDirector/PDMR Shareholding
6th Feb 202410:05 amRNSDirector/PDMR Shareholding
6th Feb 20247:00 amRNSBoard and Committee Changes
5th Feb 202412:25 pmRNSDirector/PDMR Shareholding
5th Feb 202412:20 pmRNSDirector/PDMR Shareholding
5th Feb 202412:15 pmRNSDirector/PDMR Shareholding
2nd Feb 202412:00 pmRNSBAT and PMI Announce Global Patent Settlement
1st Feb 202412:45 pmRNSTotal Voting Rights
15th Jan 20242:00 pmRNSDirector/PDMR Shareholding
4th Jan 202412:30 pmRNSDirector/PDMR Shareholding
2nd Jan 202411:10 amRNSBlock listing Interim Review
2nd Jan 202410:15 amRNSTotal Voting Rights
19th Dec 20234:45 pmRNSHolding(s) in Company
12th Dec 20237:00 amRNSBranch Register: Dividend Finalisation Information
11th Dec 202310:35 amRNSHolding(s) in Company
11th Dec 202310:30 amRNSDirector/PDMR Shareholding
7th Dec 20233:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.